Steven M Kawut

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1387290/publications.pdf

Version: 2024-02-01

185 papers 11,721 citations

28190 55 h-index 30848 102 g-index

186 all docs

186 docs citations

186 times ranked 10918 citing authors

#	Article	IF	CITATIONS
1	A Survey of Implementation of ABCDE Protocols. Journal of Intensive Care Medicine, 2023, 38, 86-94.	1.3	1
2	Insulin Resistance Is Associated with Right Ventricular Dysfunction. Annals of the American Thoracic Society, 2022, 19, 562-571.	1.5	0
3	Physical Activity and Its Association with Traditional Outcome Measures in Pulmonary Arterial Hypertension. Annals of the American Thoracic Society, 2022, 19, 572-582.	1.5	6
4	A Semi-Automated Term Harmonization Pipeline Applied to Pulmonary Arterial Hypertension Clinical Trials. Methods of Information in Medicine, 2022, 61, 003-010.	0.7	4
5	Impact of Maternal–Fetal Environment on Mortality in Children With Single Ventricle Heart Disease. Journal of the American Heart Association, 2022, 11, e020299.	1.6	14
6	Remote 6-Minute-Walk Testing in Patients with Pulmonary Hypertension: A Pilot Study. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 851-854.	2.5	8
7	BMI and Treatment Response in Patients With Pulmonary Arterial Hypertension. Chest, 2022, 162, 436-447.	0.4	6
8	Hispanic Ethnicity and Social Determinants of Health in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry. Annals of the American Thoracic Society, 2022, 19, 1459-1468.	1.5	13
9	Associations of Monocyte Count and Other Immune Cell Types with Interstitial Lung Abnormalities. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 795-805.	2.5	11
10	Impact of hepatopulmonary syndrome in liver transplantation candidates and the role of angiogenesis. European Respiratory Journal, 2022, 60, 2102304.	3.1	12
11	Secular and Regional Trends among Pulmonary Arterial Hypertension Clinical Trial Participants. Annals of the American Thoracic Society, 2022, 19, 952-961.	1.5	12
12	Genome-wide association analysis reveals insights into the genetic architecture of right ventricular structure and function. Nature Genetics, 2022, 54, 783-791.	9.4	19
13	Estrogen Signaling and Portopulmonary Hypertension: The Pulmonary Vascular Complications of Liver Disease Study (PVCLD2). Hepatology, 2021, 73, 726-737.	3.6	24
14	Noninvasive Ventilation Use Is Associated with Better Survival in Amyotrophic Lateral Sclerosis. Annals of the American Thoracic Society, 2021, 18, 486-494.	1.5	27
15	EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHAR. European Respiratory Journal, 2021, 57, 2000414.	3.1	24
16	Clinical Differences and Outcomes between Methamphetamine-associated and Idiopathic Pulmonary Arterial Hypertension in the Pulmonary Hypertension Association Registry. Annals of the American Thoracic Society, 2021, 18, 613-622.	1.5	27
17	Preoperative echocardiographic parameters predict primary graft dysfunction following pediatric lung transplantation. Pediatric Transplantation, 2021, 25, e13858.	0.5	6
18	Sex Differences in Portopulmonary Hypertension. Chest, 2021, 159, 328-336.	0.4	7

#	Article	IF	Citations
19	Longitudinal Associations of Fitness and Obesity in Young Adulthood With Right Ventricular Function and Pulmonary Artery Systolic Pressure in Middle Age: The CARDIA Study. Journal of the American Heart Association, 2021, 10, e016968.	1.6	10
20	Risk of primary graft dysfunction following lung transplantation in selected adults with connective tissue disease-associated interstitial lung disease. Journal of Heart and Lung Transplantation, 2021, 40, 351-358.	0.3	7
21	Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop. Circulation: Heart Failure, 2021, 14, .	1.6	11
22	Identifying Risk Factors for Complicated Post-operative Course in Tetralogy of Fallot Using a Machine Learning Approach. Frontiers in Cardiovascular Medicine, 2021, 8, 685855.	1.1	7
23	Associations of Angiopoietins With Heart Failure Incidence and Severity. Journal of Cardiac Failure, 2021, 27, 786-795.	0.7	12
24	Loss of Pulmonary Vascular Volume as a Predictor of Right Ventricular Dysfunction and Mortality in Acute Pulmonary Embolism. Circulation: Cardiovascular Imaging, 2021, 14, e012347.	1.3	9
25	Prescription Patterns for Pulmonary Vasodilators in the Treatment of Pulmonary Hypertension Associated With Chronic Lung Diseases: Insights From a Clinician Survey. Frontiers in Medicine, 2021, 8, 764815.	1.2	1
26	The presence of Aspergillus fumigatus is associated with worse respiratory quality of life in cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 125-130.	0.3	28
27	Associations of Serum Adipokines With Subclinical Interstitial Lung Disease Among Community-Dwelling Adults. Chest, 2020, 157, 580-589.	0.4	17
28	Investigational new drug enabling angiotensin oral-delivery studies to attenuate pulmonary hypertension. Biomaterials, 2020, 233, 119750.	5.7	42
29	Endothelin-1, cardiac morphology, and heart failure: the MESA angiogenesis study. Journal of Heart and Lung Transplantation, 2020, 39, 45-52.	0.3	12
30	Regional distribution of high-attenuation areas on chest computed tomography in the Multi-Ethnic Study of Atherosclerosis. ERJ Open Research, 2020, 6, 00115-2019.	1.1	9
31	Risk factors for 30â€day readmission in adults hospitalized for pulmonary hypertension. Pulmonary Circulation, 2020, 10, 1-14.	0.8	3
32	Prevalence and Impact of Restrictive Lung Disease in Liver Transplant Candidates. Liver Transplantation, 2020, 26, 989-999.	1.3	5
33	Age-related differences in hemodynamics and functional status in pulmonary arterial hypertension: Baseline results from the Pulmonary Hypertension Association Registry. Journal of Heart and Lung Transplantation, 2020, 39, 945-953.	0.3	15
34	BMP9/10 in Pulmonary Vascular Complications of Liver Disease. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1575-1578.	2.5	32
35	Antinuclear antibodies and subclinical interstitial lung disease in community-dwelling adults: the MESA study. European Respiratory Journal, 2020, 55, 1902262.	3.1	1
36	Association of right atrial structure with incident atrial fibrillation: a longitudinal cohort cardiovascular magnetic resonanceÂstudy from the Multi-Ethnic Study of AtherosclerosisÂ(MESA). Journal of Cardiovascular Magnetic Resonance, 2020, 22, 36.	1.6	26

3

#	Article	IF	CITATIONS
37	Association between antinuclear antibody seropositivity and telomere length: a nationwide population-based study. Clinical and Experimental Rheumatology, 2020, 38, 989-992.	0.4	O
38	Inhaled antibiotic use is associated with <i>Scedosporium/Lomentospora</i> species isolation in cystic fibrosis. Pediatric Pulmonology, 2019, 54, 133-140.	1.0	14
39	Pulse Oximetry Is Insensitive for Detection of Hepatopulmonary Syndrome in Patients Evaluated for Liver Transplantation. Hepatology, 2019, 69, 270-281.	3.6	36
40	Predicting respiratory failure in amyotrophic lateral sclerosis: still a long way to go. European Respiratory Journal, 2019, 54, 1901221.	3.1	0
41	Circulating adhesion molecules and subclinical interstitial lung disease: the Multi-Ethnic Study of Atherosclerosis. European Respiratory Journal, 2019, 54, 1900295.	3.1	16
42	Classifying Patients with Amyotrophic Lateral Sclerosis by Changes in FVC. A Group-based Trajectory Analysis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1513-1521.	2.5	21
43	Response. Chest, 2019, 156, 187-188.	0.4	0
44	2-Year Outcomes After Complete or Staged Procedure for TetralogyÂofÂFallotÂin Neonates. Journal of the American College of Cardiology, 2019, 74, 1570-1579.	1.2	49
45	Ambient air pollution and pulmonary vascular volume on computed tomography: the MESA Air Pollution and Lung cohort studies. European Respiratory Journal, 2019, 53, 1802116.	3.1	18
46	The Post–Pulmonary Embolism Syndrome: Real or Ruse?. Annals of the American Thoracic Society, 2019, 16, 811-814.	1.5	26
47	Statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute (PVRI). Pulmonary Circulation, 2019, 9, 1-32.	0.8	96
48	Right ventricular outflow tract velocity time integral-to-pulmonary artery systolic pressure ratio: a non-invasive metric of pulmonary arterial compliance differs across the spectrum of pulmonary hypertension. Pulmonary Circulation, 2019, 9, 204589401984197.	0.8	11
49	Development of a prognostic model of respiratory insufficiency or death in amyotrophic lateral sclerosis. European Respiratory Journal, 2019, 53, 1802237.	3.1	30
50	Sorafenib in Hepatopulmonary Syndrome: A Randomized, Doubleâ€Blind, Placeboâ€Controlled Trial. Liver Transplantation, 2019, 25, 1155-1164.	1.3	26
51	Portopulmonary Hypertension: A Survey of Practice Patterns and Provider Attitudes. Transplantation Direct, 2019, 5, e456.	0.8	17
52	New and Emerging Therapies for Pulmonary Arterial Hypertension. Annual Review of Medicine, 2019, 70, 45-59.	5.0	68
53	Therapy for Pulmonary Arterial Hypertension in Adults. Chest, 2019, 155, 565-586.	0.4	216
54	Risk factors for persistent Aspergillus respiratory isolation in cystic fibrosis. Journal of Cystic Fibrosis, 2018, 17, 624-630.	0.3	43

#	Article	IF	CITATIONS
55	Association of long pentraxin-3 with pulmonary hypertension and primary graft dysfunction in lung transplant recipients. Journal of Heart and Lung Transplantation, 2018, 37, 792-794.	0.3	6
56	Right ventricular function mirrors clinical improvement with use of prostacyclin analogues in pediatric pulmonary hypertension. Pulmonary Circulation, 2018, 8, 1-8.	0.8	23
57	Pulmonary artery stiffness in chronic obstructive pulmonary disease (COPD) and emphysema: The Multiâ€Ethnic Study of Atherosclerosis (MESA) COPD Study. Journal of Magnetic Resonance Imaging, 2018, 47, 262-271.	1.9	8
58	Associations between emphysema-like lung on CT and incident airflow limitation: a general population-based cohort study. Thorax, 2018, 73, 486-488.	2.7	19
59	Clinical Impact of Intrapulmonary Vascular Dilatation in Candidates for Liver Transplant. Chest, 2018, 153, 414-426.	0.4	16
60	Features and Outcomes of Methamphetamine-associated Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 788-800.	2.5	81
61	Quantitative Evidence for Revising the Definition of Primary Graft Dysfunction after Lung Transplant. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 235-243.	2.5	45
62	Histamine H2 Receptor Polymorphisms, Myocardial Transcripts, and Heart Failure (from the) Tj ETQq0 0 0 rgBT /	Overlock 1 0.7	10 Tf 50 467 T 13
63	The Impact of Pulmonary Hypertension in Preterm Infants with Severe Bronchopulmonary Dysplasia through 1 Year. Journal of Pediatrics, 2018, 203, 218-224.e3.	0.9	87
64	Predictors of Length of Hospital Stay After Complete Repair for Tetralogy of Fallot: A Prospective Cohort Study. Journal of the American Heart Association, 2018, 7, .	1.6	30
65	Lower DHEA-S levels predict disease and worse outcomes in post-menopausal women with idiopathic, connective tissue disease- and congenital heart disease-associated pulmonary arterial hypertension. European Respiratory Journal, 2018, 51, 1800467.	3.1	54
66	Assessment of Right Ventricular Function in the Research Setting: Knowledge Gaps and Pathways Forward. An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine, 2018, 198, e15-e43.	2.5	220
67	Collagen biomarkers and subclinical interstitial lung disease: The Multi-Ethnic Study of Atherosclerosis. Respiratory Medicine, 2018, 140, 108-114.	1.3	11
68	Cell-free hemoglobin promotes primary graft dysfunction through oxidative lung endothelial injury. JCI Insight, 2018, 3, .	2.3	35
69	The Pulmonary Hypertension Association Registry: Rationale, Design, and Role in Quality Improvement. Advances in Pulmonary Hypertension, 2018, 16, 185-188.	0.1	23
70	Anastrozole in Pulmonary Arterial Hypertension. A Randomized, Double-Blind, Placebo-controlled Trial. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 360-368.	2.5	88
71	Percent Emphysema and Daily Motor Activity Levels in the General Population. Chest, 2017, 151, 1039-1050.	0.4	10
72	Right Ventricular Structure and Function Are Associated With Incident Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	2.1	20

#	Article	IF	CITATIONS
73	Cholesterol, lipoproteins and subclinical interstitial lung disease: the MESA study. Thorax, 2017, 72, 472-474.	2.7	29
74	Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI–Cardiovascular Medical Research and Education Fund Workshop Report. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1661-1670.	2.5	59
75	Obstructive Sleep Apnea and Subclinical Interstitial Lung Disease in the Multi-Ethnic Study of Atherosclerosis (MESA). Annals of the American Thoracic Society, 2017, 14, 1786-1795.	1.5	60
76	Antacid use and subclinical interstitial lung disease: the MESA study. European Respiratory Journal, 2017, 49, 1602566.	3.1	5
77	Slow-paced respiration therapy to treat symptoms in pulmonary arterial hypertension. Heart and Lung: Journal of Acute and Critical Care, 2017, 46, 7-13.	0.8	8
78	Health Disparities in Patients with Pulmonary Arterial Hypertension: A Blueprint for Action. An Official American Thoracic Society Statement. American Journal of Respiratory and Critical Care Medicine, 2017, 196, e32-e47.	2.5	36
79	Racial and ethnic differences in pulmonary arterial hypertension. Pulmonary Circulation, 2017, 7, 793-796.	0.8	38
80	Magnetic Resonance Imaging in Pulmonary Arterial Hypertension. Panacea or Pixelation?. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 129-131.	2.5	1
81	Occupational Exposures and Subclinical Interstitial Lung Disease. The MESA (Multi-Ethnic Study of) Tj ETQq1 1 2017, 196, 1031-1039.	0.784314 (2 . 5	gBT /Overloc 46
82	Report of the International Society for Heart and Lung Transplantation Working Group on Primary Lung Graft Dysfunction, part II: Epidemiology, risk factors, and outcomesâ€"A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation. Journal of Heart and Lung Transplantation, 2017, 36, 1104-1113.	0.3	114
83	Inhibiting oestrogen signalling in pulmonary arterial hypertension: sex, drugs and research. European Respiratory Journal, 2017, 50, 1700983.	3.1	11
84	Genome-wide association study of subclinical interstitial lung disease in MESA. Respiratory Research, 2017, 18, 97.	1.4	31
85	Tracheobronchomalacia Is Associated with Increased Morbidity in Bronchopulmonary Dysplasia. Annals of the American Thoracic Society, 2017, 14, 1428-1435.	1.5	90
86	Pulmonary vascular volume, impaired left ventricular filling and dyspnea: The MESA Lung Study. PLoS ONE, 2017, 12, e0176180.	1.1	50
87	Pulmonary hyperinflation due to gas trapping and pulmonary artery size: The MESA COPD Study. PLoS ONE, 2017, 12, e0176812.	1.1	10
88	Ambient Coarse Particulate Matter and the Right Ventricle: The Multi-Ethnic Study of Atherosclerosis. Environmental Health Perspectives, 2017, 125, 077019.	2.8	6
89	Particulate Matter Exposure and Cardiopulmonary Differences in the Multi-Ethnic Study of Atherosclerosis. Environmental Health Perspectives, 2016, 124, 1166-1173.	2.8	23
90	Association of Systemic Arterial Properties With Right Ventricular Morphology: The Multiâ€Ethnic Study of Atherosclerosis (MESA)â€Right Ventricle Study. Journal of the American Heart Association, 2016, 5, .	1.6	13

#	Article	IF	CITATIONS
91	Rheumatoid arthritis-associated autoantibodies and subclinical interstitial lung disease: the Multi-Ethnic Study of Atherosclerosis. Thorax, 2016, 71, 1082-1090.	2.7	59
92	Per cent emphysema is associated with respiratory and lung cancer mortality in the general population: a cohort study. Thorax, 2016, 71, 624-632.	2.7	61
93	The relationship between plasma lipid peroxidation products and primary graft dysfunction after lung transplantation is modified by donor smoking and reperfusion hyperoxia. Journal of Heart and Lung Transplantation, 2016, 35, 500-507.	0.3	30
94	High attenuation areas on chest computed tomography in community-dwelling adults: the MESA study. European Respiratory Journal, 2016, 48, 1442-1452.	3.1	110
95	Determinants of 6â€Minute Walk Distance in Patients with Idiopathic Pulmonary Fibrosis Undergoing Lung Transplant Evaluation. Pulmonary Circulation, 2016, 6, 30-36.	0.8	5
96	Diastolic Dysfunction Increases the Risk of Primary Graft Dysfunction after Lung Transplant. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 1392-1400.	2.5	58
97	Higher Estradiol and Lower Dehydroepiandrosterone-Sulfate Levels Are Associated with Pulmonary Arterial Hypertension in Men. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 1168-1175.	2.5	104
98	Oestradiol metabolism and androgen receptor genotypes are associated with right ventricular function. European Respiratory Journal, 2016, 47, 553-563.	3.1	54
99	BMPR2 revisited: are bigger data better?. Lancet Respiratory Medicine,the, 2016, 4, 87-89.	5. 2	0
100	Histamine H 2 Receptor Antagonists, LeftÂVentricular Morphology, and HeartÂFailureÂRisk. Journal of the American College of Cardiology, 2016, 67, 1544-1552.	1.2	54
101	A global view of pulmonary hypertension. Lancet Respiratory Medicine, the, 2016, 4, 306-322.	5.2	523
102	Prognostic Significance of Biomarkers in Pulmonary Arterial Hypertension. Annals of the American Thoracic Society, 2016, 13, 25-30.	1.5	53
103	A prospective study of the 6â€min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naÃ⁻ve systemic sclerosis-associated pulmonary arterial hypertension. Annals of the Rheumatic Diseases, 2016, 75, 1457-1465.	0.5	16
104	Pericardial Fat and Right Ventricular Morphology: The Multi-Ethnic Study of Atherosclerosis- Right Ventricle Study (MESA-RV). PLoS ONE, 2016, 11, e0157654.	1.1	8
105	Adverse Events in Connective Tissue Disease–Associated Pulmonary Arterial Hypertension. Arthritis and Rheumatology, 2015, 67, 2457-2465.	2.9	12
106	Adipokines and the Right Ventricle: The MESA-RV Study. PLoS ONE, 2015, 10, e0136818.	1.1	6
107	Pulmonary Microvascular Blood Flow in Mild Chronic Obstructive Pulmonary Disease and Emphysema. The MESA COPD Study. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 570-580.	2.5	127
108	What is new about Rio?. European Respiratory Journal, 2015, 45, 1211-1213.	3.1	2

#	Article	IF	CITATIONS
109	Profiling the Role of Mammalian Target of Rapamycin in the Vascular Smooth Muscle Metabolome in Pulmonary Arterial Hypertension. Pulmonary Circulation, 2015, 5, 667-680.	0.8	19
110	Interleukin-6 and Tumor Necrosis Factor-α Are Associated with Quality of Life–Related Symptoms in Pulmonary Arterial Hypertension. Annals of the American Thoracic Society, 2015, 12, 370-375.	1.5	31
111	What's the (end) point?. European Respiratory Journal, 2015, 45, 853-854.	3.1	3
112	Predictors of Catastrophic AdverseÂOutcomes in Children With Pulmonary Hypertension Undergoing Cardiac Catheterization. Journal of the American College of Cardiology, 2015, 66, 1261-1269.	1.2	57
113	Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction. European Respiratory Journal, 2015, 46, 1370-1377.	3.1	129
114	Update in Pulmonary Vascular Diseases 2014. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 544-550.	2.5	7
115	Noninvasive Tests for the Diagnostic Evaluation of Dyspnea Among Outpatients: The Multi-Ethnic Study of Atherosclerosis Lung Study. American Journal of Medicine, 2015, 128, 171-180.e5.	0.6	22
116	Intravenous Immunoglobulin for Hypogammaglobulinemia after Lung Transplantation: A Randomized Crossover Trial. PLoS ONE, 2014, 9, e103908.	1.1	14
117	Traffic-related Air Pollution and the Right Ventricle. The Multi-ethnic Study of Atherosclerosis. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1093-1100.	2.5	54
118	Pentraxinâ€3 and the Right Ventricle: The Multiâ€Ethnic Study of Atherosclerosis–Right Ventricle Study. Pulmonary Circulation, 2014, 4, 250-259.	0.8	11
119	H ₂ Receptor Antagonists and Right Ventricular Morphology: The MESA Right Ventricle Study. Annals of the American Thoracic Society, 2014, 11, 1379-1386.	1.5	18
120	Sex and haemodynamics in pulmonary arterial hypertension. European Respiratory Journal, 2014, 43, 523-530.	3.1	89
121	Connective tissue disease-associated pulmonary arterial hypertension: "Beijing style― European Respiratory Journal, 2014, 44, 839-841.	3.1	4
122	Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study. American Heart Journal, 2014, 167, 218-225.e1.	1.2	27
123	Validity of the Surface Electrocardiogram Criteria for Right Ventricular Hypertrophy. Journal of the American College of Cardiology, 2014, 63, 672-681.	1.2	36
124	Mammalian Target of Rapamycin Complex 2 (mTORC2) Coordinates Pulmonary Artery Smooth Muscle Cell Metabolism, Proliferation, and Survival in Pulmonary Arterial Hypertension. Circulation, 2014, 129, 864-874.	1.6	162
125	Cor Pulmonale Parvus in Chronic Obstructive Pulmonary Disease and Emphysema. Journal of the American College of Cardiology, 2014, 64, 2000-2009.	1.2	76
126	Are Hemodynamics Surrogate End Points in Pulmonary Arterial Hypertension?. Circulation, 2014, 130, 768-775.	1.6	46

#	Article	IF	Citations
127	Reply. Journal of the American College of Cardiology, 2014, 64, 739.	1.2	O
128	Impact of the Hepatopulmonary Syndrome MELD Exception Policy on Outcomes of Patients After Liver Transplantation: An Analysis of the UNOS Database. Gastroenterology, 2014, 146, 1256-1265.e1.	0.6	105
129	An Official American Thoracic Society Statement: Pulmonary Hypertension Phenotypes. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 345-355.	2.5	70
130	Erythropoietin Upregulation in Pulmonary Arterial Hypertension. Pulmonary Circulation, 2014, 4, 269-279.	0.8	18
131	Not All Measures of Hyperinflation Are Created Equal. Chest, 2014, 145, 1305-1315.	0.4	22
132	The Right Ventricle Explains Sex Differences in Survival in Idiopathic Pulmonary Arterial Hypertension. Chest, 2014, 145, 1230-1236.	0.4	166
133	Right Heart Adaptation to Pulmonary ArterialÂHypertension. Journal of the American College of Cardiology, 2013, 62, D22-D33.	1.2	770
134	Tricuspid Annular Plane Systolic Excursion in the Assessment of Right Ventricular Function in Children and Adolescents after Repair of Tetralogy of Fallot. Journal of the American Society of Echocardiography, 2013, 26, 1322-1329.	1.2	68
135	Relax or Contract. Circulation, 2013, 128, 1999-2001.	1.6	2
136	Advancing Clinical Trial Design in Pulmonary Hypertension. Pulmonary Circulation, 2013, 3, 217-225.	0.8	16
137	Clinical Risk Factors for Primary Graft Dysfunction after Lung Transplantation. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 527-534.	2.5	529
138	Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan. Annals of Internal Medicine, 2013, 158, 641.	2.0	437
139	Percent Emphysema and Right Ventricular Structure and Function. Chest, 2013, 144, 136-144.	0.4	75
140	Latent Class Analysis Identifies Distinct Phenotypes of Primary Graft Dysfunction After Lung Transplantation. Chest, 2013, 144, 616-622.	0.4	48
141	Baseline and Follow-up 6-Min Walk Distance and Brain Natriuretic Peptide Predict 2-Year Mortality in Pulmonary Arterial Hypertension. Chest, 2013, 143, 315-323.	0.4	90
142	Echocardiographic and Hemodynamic Predictors of Mortality in Idiopathic Pulmonary Fibrosis. Chest, 2013, 144, 564-570.	0.4	99
143	Right Ventricular Morphology and the Onset of Dyspnea: The MESA-Right Ventricle Study. PLoS ONE, 2013, 8, e56826.	1.1	8
144	Brachial Artery Diameter and the Right Ventricle. Chest, 2012, 142, 1399-1405.	0.4	11

#	Article	IF	Citations
145	Obesity and Right Ventricular Structure and Function. Chest, 2012, 141, 388-395.	0.4	116
146	Race and Sex Differences in Response to Endothelin Receptor Antagonists for Pulmonary Arterial Hypertension. Chest, 2012, 141, 20-26.	0.4	129
147	Validation of 6-Minute Walk Distance as a Surrogate End Point in Pulmonary Arterial Hypertension Trials. Circulation, 2012, 126, 349-356.	1.6	211
148	Right Ventricular Structure Is Associated With the Risk of Heart Failure and Cardiovascular Death. Circulation, 2012, 126, 1681-1688.	1.6	145
149	Von Willebrand Factor and the Right Ventricle (the MESA-Right Ventricle Study). American Journal of Cardiology, 2012, 110, 1846-1851.	0.7	5
150	Selective Serotonin Reuptake Inhibitor Use Is Associated with Right Ventricular Structure and Function: The MESA-Right Ventricle Study. PLoS ONE, 2012, 7, e30480.	1.1	11
151	Lung Retransplantation. Clinics in Chest Medicine, 2011, 32, 367-377.	0.8	39
152	Rationale and design of a phase II clinical trial of aspirin and simvastatin for the treatment of pulmonary arterial hypertension: ASA-STAT. Contemporary Clinical Trials, 2011, 32, 280-287.	0.8	8
153	Sex Hormones Are Associated with Right Ventricular Structure and Function. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 659-667.	2.5	156
154	Randomized Clinical Trial of Aspirin and Simvastatin for Pulmonary Arterial Hypertension. Circulation, 2011, 123, 2985-2993.	1.6	127
155	Physical Activity and Right Ventricular Structure and Function. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 396-404.	2.5	69
156	Elevated Pulmonary Artery Pressure Is a Risk Factor for Primary Graft Dysfunction Following Lung Transplantation for Idiopathic Pulmonary Fibrosis. Chest, 2011, 139, 782-787.	0.4	85
157	Regional Left Ventricular Systolic Function and the Right Ventricle. Chest, 2011, 140, 310-316.	0.4	18
158	Effect of Single vs Bilateral Lung Transplantation on Plasma Surfactant Protein D Levels in Idiopathic Pulmonary Fibrosis. Chest, 2011, 140, 489-496.	0.4	18
159	Sex and Race Differences in Right Ventricular Structure and Function. Circulation, 2011, 123, 2542-2551.	1.6	288
160	Performance of American Thoracic Society-Recommended Spirometry Reference Values in a Multiethnic Sample of Adults. Chest, 2010, 137, 138-145.	0.4	214
161	Relation of Cardiovascular Risk Factors to Right Ventricular Structure and Function as Determined by Magnetic Resonance Imaging (Results from the Multi-Ethnic Study of Atherosclerosis). American Journal of Cardiology, 2010, 106, 110-116.	0.7	57
162	Percent Emphysema, Airflow Obstruction, and Impaired Left Ventricular Filling. New England Journal of Medicine, 2010, 362, 217-227.	13.9	473

#	Article	IF	Citations
163	Matrix metalloproteinase-9 and plasminogen activator inhibitor-1 are associated with right ventricular structure and function: The MESA-RV Study. Biomarkers, 2010, 15, 731-738.	0.9	17
164	Impact of Pulmonary Artery Pressure on Exercise Function in Severe COPD. Chest, 2009, 136, 412-419.	0.4	107
165	Soluble P-Selectin and the Risk of Primary Graft Dysfunction After Lung Transplantation. Chest, 2009, 136, 237-244.	0.4	34
166	Genetic Risk Factors for Portopulmonary Hypertension in Patients with Advanced Liver Disease. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 835-842.	2.5	206
167	Serum Albumin Concentration and Waiting List Mortality in Idiopathic Interstitial Pneumonia. Chest, 2009, 135, 929-935.	0.4	48
168	Determinants of Right Ventricular Ejection Fraction in Pulmonary Arterial Hypertension. Chest, 2009, 135, 752-759.	0.4	116
169	Serotonin Transporter Polymorphisms in Patients With Portopulmonary Hypertension. Chest, 2009, 135, 1470-1475.	0.4	38
170	SIX-MINUTE WALK DISTANCE AND B-TYPE NATRIURETIC PEPTIDE AS DISCRIMINATORS OF SURVIVAL IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION. Chest, 2009, 136, 22S.	0.4	1
171	Impact of Hepatopulmonary Syndrome on Quality of Life and Survival in Liver Transplant Candidates. Gastroenterology, 2008, 135, 1168-1175.	0.6	236
172	Plasma serotonin levels are normal in pulmonary arterial hypertension. Pulmonary Pharmacology and Therapeutics, 2008, 21, 112-114.	1,1	25
173	Surrogate and Combined End Points in Pulmonary Arterial Hypertension. Proceedings of the American Thoracic Society, 2008, 5, 617-622.	3.5	35
174	Outcomes after Lung Retransplantation in the Modern Era. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 114-120.	2.5	116
175	Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis. Chest, 2007, 132, 998-1006.	0.4	223
176	Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension. Pulmonary Pharmacology and Therapeutics, 2006, 19, 370-374.	1.1	59
177	Immunoglobulin G Levels before and after Lung Transplantation. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 917-921.	2.5	57
178	Outcomes of Extended Donor Lung Recipients after Lung Transplantation. Transplantation, 2005, 79, 310-316.	0.5	52
179	Risk Factors and Outcomes of Hypogammaglobulinemia after Lung Transplantation. Transplantation, 2005, 79, 1723-1726.	0.5	38
180	von Willebrand Factor Independently Predicts Long-term Survival in Patients With Pulmonary Arterial Hypertension. Chest, 2005, 128, 2355-2362.	0.4	75

#	Article	IF	CITATIONS
181	New predictors of outcome in idiopathic pulmonary arterial hypertension. American Journal of Cardiology, 2005, 95, 199-203.	0.7	227
182	Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transplantation, 2005, 11, 1107-1111.	1.3	154
183	Exercise testing determines survival in patients with diffuse parenchymal lung disease evaluated for lung transplantation. Respiratory Medicine, 2005, 99, 1431-1439.	1.3	90
184	Hemodynamics and Survival in Patients With Pulmonary Arterial Hypertension Related to Systemic Sclerosis*. Chest, 2003, 123, 344-350.	0.4	403
185	Reply to: Remote 6-minute Walk Testing in Patients with Pulmonary Hypertension: Further Validation Needed?. American Journal of Respiratory and Critical Care Medicine, 0, , .	2.5	0